We are developing CMD-501 for the treatment of neuroblastoma and small cell lung cancer. CMD-501 is an autologous cell therapy which utilizes our natural killer T (NKT) cell platform technology in combination with genetically engineered chimeric antigen receptors (CARs) and secretion of the IL-15 cytokine to sustain the activity of the therapeutic cells within the immunosuppressive tumor microenvironment. A Phase 1 trial evaluating CMD-501 for safety and activity in pediatric patients with neuroblastoma is being sponsored and conducted by Baylor College of Medicine (BCM) at Texas Children’s Hospital in Houston, TX
We are developing CMD-501 in neuroblastoma as the lead indication and proof of concept. We will then broaden the application of CMD-501 to the lung cancer indication.
The BCM GINAKIT2 Phase 1 clinical trial is evaluating CMD-501 (CAR.GD2-IL-15 NKTs), a new cancer immunotherapy that uses natural killer T (NKT) cells, in children with neuroblastoma. This study will be the first to use genetically engineered NKT cells in humans.
Information on the clinical trial can be found here: https://www.bcm.edu/research/clinical-trials/h-41033